EN DE
Watch 160 Health International Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

160 Health International Ltd (2656) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of 160 Health International Ltd stock HK$0.69, price HK$3.53, that is 80.5% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

1H 160 Health International Ltd logo Thin data Nov 8, 2026

160 Health International Ltd

2656 · HK
Very expensive, weak quality

Our calculation puts a fair price 80% below what the stock costs today.

Low debt
Quality 43/100
Expensive Growth (revenue 3y +7.4 %/yr in CNY)
Revenue last quarter 16% below a year ago.
Fair value HK$0.6900 · Strongly overvalued (−80.5%)
Loss-making · -7.6% net margin (TTM)
Negative free cash flow
Trails peers (1/10)
Narrow moat 13/100 · thin data
Thin data
Watch 160 Health International Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$151.00 HK$2.15 Fair Value HK$0.6900 Sep 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

14‑month range HK$2.15 – HK$151.00 · fair‑value band HK$0.4600 – HK$0.8600 · the HK$3.53 price screens above the HK$0.6900 fair value. As of Nov 8, 2026.

Follow 160 Health International in your weekly email

Every Wednesday you see whether 160 Health International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

160 Health International Limited wholesales and retails pharmaceutical and healthcare products in China.

Show moreShow less

Thedevelops Healthcare 160 Platform, an online healthcare and wellness service platform which provides digital healthcare and wellness solutions, including online marketing solutions, digital hospital solutions, and online healthcare services to business customers, medical and healthcare institutions, medical professionals, individual users, and third-party merchants. 160 Health International Limited was founded in 2005 and is headquartered in Shenzhen, the People's Republic of China.

Stock analysis

160 Health International Ltd (2656) currently trades at HK$3.53, while our model-based Fair Value estimate is HK$0.6900, 80% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the data coverage at low.

Scenario range: HK$0.4600 (bear) to HK$0.8600 (bull), the price of HK$3.53 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

160 Health International Ltd reported revenue of 652M CNY in FY2025 versus 526M CNY in FY2022, a compound +7.4%/yr. Reported net income was −73.0M CNY in FY2025.

Key figures

Market cap HK$1.2B (≈ $151M) Micro · P/S ratio 1.16 · Net margin −11.2% · Return on equity −78.5% · Return on assets (EBIT) −32.5% (4-year average) · Operating margin 1.7% · Revenue (TTM) 680M CNY · Revenue growth (YoY) −16.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 98% below its 52-week high and 65% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at −80%, 2656 screens richer than that median.

Fair Value models

Bear HK$0.4600 Fair Value HK$0.6900 Bull HK$0.8600
Price HK$3.53 · Downside -80.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$0.4600 HK$0.6900 HK$0.8600 55
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.4600 HK$0.6900 HK$0.8600 55

Open the full fair value analysis →

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+5.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−15.1% (2022) → −9.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2656 screens overvalued: fair value 80% below the price. Compare with McKesson Corporation →

Compare 160 Health International Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 77 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −80.5% · Bottom 25%
Profitability
Return on assets −9.6% · Bottom 25%
Net margin (12 months) −7.6% · Bottom 25%
Operating margin (12 months) 1.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −16.2% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 4.22× · Priciest 25%
P/S (12 months) 1.49× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 38
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 28
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 54

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$17.16 HK$51.48 +200% vs 2656
Jointown Pharmaceutical Group 600998 ¥5.24 ¥11.56 +121% vs 2656
Shanghai Pharmaceuticals Holding 601607 ¥16.76 ¥35.78 +113% vs 2656
China National Medicines Corporation 600511 ¥29.29 ¥58.47 +100% vs 2656
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥20.09 ¥26.64 +33% vs 2656
Cencora, Inc COR $333.56 $341.58 +2% vs 2656
Henry Schein, Inc HSIC $86.05 $78.69 −9% vs 2656
McKesson Corporation MCK $1,061 $822.74 −22% vs 2656
Galenica AG GALE CHF 89.45 CHF 61.79 −31% vs 2656
Cardinal Health, Inc CAH $271.72 $163.14 −40% vs 2656

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

160 Health International Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "160 Health International Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2656

Frequently asked questions

Is 160 Health International Ltd (2656) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of HK$0.6900 versus a price of HK$3.53, about 80% lower (overvalued).
What is the fair value of 2656?
Our model-based fair value for 160 Health International Ltd is HK$0.6900 (as of Nov 8, 2026), built from audited fundamentals. The current price: HK$3.53.
What is the quality score of 2656?
160 Health International Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 160 Health International Ltd (2656)?
Our model-based price target is the fair value of HK$0.6900 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario HK$0.4600, optimistic scenario HK$0.8600. It is a calculation from audited fundamentals, not an analyst target.
What is the 160 Health International Ltd stock forecast for 2026?
Our models put fair value at HK$0.6900, about 80% lower versus a price of HK$3.53 (overvalued). Cautious scenario HK$0.4600, optimistic scenario HK$0.8600. The calculation is refreshed regularly with new filings.
What is the revenue of 160 Health International Ltd (2656)?
160 Health International Ltd reported trailing-twelve-month revenue of about 680M CNY (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of 160 Health International Ltd (2656)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 160 Health International Ltd it is HK$0.6900 per share (as of Nov 8, 2026), against a price of HK$3.53. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is 160 Health International Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, 2656 trades above its calculated fair value: price HK$3.53, fair value HK$0.6900, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2656?
No. The price is what the market pays today (HK$3.53); the fair value is what the company's own numbers justify (HK$0.6900). For 160 Health International Ltd the two are HK$2.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is 160 Health International Ltd worth?
The market values 160 Health International Ltd at about HK$1.2B (market capitalisation, as of Nov 8, 2026). Per share that is HK$3.53; our models calculate a fair value of HK$0.6900 per share.
What do the bullish and bearish scenarios say about 2656?
Our models span a range for 160 Health International Ltd: cautious scenario HK$0.4600, base HK$0.6900, optimistic HK$0.8600 per share (as of Nov 8, 2026, price HK$3.53). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 160 Health International Ltd (2656)?
Balance-sheet figures for 160 Health International Ltd (as of Nov 8, 2026): return on equity −78.5%, debt of 0.01 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 2656 from its 52-week high?
160 Health International Ltd trades at HK$3.53, about 98% below its 52-week high of HK$151.00 and 65% above the low of HK$2.15 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.6900 is for.
Which stocks are comparable to 160 Health International Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 160 Health International Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price HK$3.53, calculated fair value HK$0.6900 (−80%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2656 calculated?
We run 160 Health International Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$0.6900 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. 160 Health International Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 160 Health International Ltd (2656)?
The closing price on Nov 6, 2026 was HK$3.53. Our model-based fair value is HK$0.6900, about 80% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 160 Health International Ltd right now?
The price sits above even our optimistic bull case (HK$0.8600). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$0.4600 to HK$0.8600) leaves room in how you read the outcome.

Key figures of 160 Health International Ltd

How large is the market capitalisation of 160 Health International Ltd (2656)?
The market capitalisation of 160 Health International Ltd is HK$1.2B (≈ $151M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 160 Health International Ltd (2656)?
The price-to-sales ratio of 160 Health International Ltd is 1.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of 160 Health International Ltd (2656)?
The net margin of 160 Health International Ltd is −11.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of 160 Health International Ltd (2656)?
The return on equity (ROE) of 160 Health International Ltd is −78.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 160 Health International Ltd (2656)?
On an EBIT basis the return on assets of 160 Health International Ltd is −32.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 160 Health International Ltd (2656)?
The operating margin of 160 Health International Ltd is 1.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 160 Health International Ltd (2656)?
Revenue at 160 Health International Ltd is growing −16.2% versus a year earlier (3y avg +7.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 160 Health International Ltd (2656) generate?
The free cash flow of 160 Health International Ltd is −119M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does 160 Health International Ltd (2656) carry?
The net debt of 160 Health International Ltd is 32.4M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch 160 Health International Ltd in the live analysis

One click puts 160 Health International Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.